Aliases & Classifications for Adenocarcinoma

MalaCards integrated aliases for Adenocarcinoma:

Name: Adenocarcinoma 12 29 52 42 14 69
Adenocarcinoma, No Subtype 12
Adenocarcinoma Nos 12
Adenocarcinomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:299
MeSH 42 D000230
NCIt 47 C2852
UMLS 69 C0001418

Summaries for Adenocarcinoma

Disease Ontology : 12 A carcinoma that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Adenocarcinoma, also known as adenocarcinoma, no subtype, is related to villous adenocarcinoma and adenocarcinoma in situ. An important gene associated with Adenocarcinoma is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Abraxane and Cervarix have been mentioned in the context of this disorder. Affiliated tissues include lung, prostate and liver, and related phenotypes are Decreased viability and cellular

Wikipedia : 72 Adenocarcinoma (/ˌædɪnoʊkɑːrsɪˈnoʊmə/; plural adenocarcinomas or adenocarcinomata... more...

Related Diseases for Adenocarcinoma

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1086)
id Related Disease Score Top Affiliating Genes
1 villous adenocarcinoma 34.3 CDKN2A ERBB2 PTGS2 TP53
2 adenocarcinoma in situ 34.3 CDKN2A KRAS TP53
3 sebaceous adenocarcinoma 34.1 EGFR KRAS MUC1 TP53
4 cecum adenocarcinoma 34.0 CDKN2A EGFR KRAS MUC1 TP53
5 urethra adenocarcinoma 34.0 CDH1 MUC1 PTGS2 TP53
6 ureter adenocarcinoma 33.9 CDH1 EGFR ERBB2 MUC1
7 colon signet ring adenocarcinoma 33.8 CTNNB1 SMAD4 TP53
8 pancreatic signet ring cell adenocarcinoma 33.7 CDH1 CTNNB1 MUC1 TP53
9 peritoneal serous adenocarcinoma 33.6 CDH1 EPCAM KRAS MUC1 TP53
10 apocrine adenocarcinoma 33.5 CDH1 CTNNB1 EGFR EPCAM KRAS MUC1
11 pancreatic cancer 33.3 CDH1 CDKN2A EGFR TP53
12 serous cystadenocarcinoma 32.1 AKT1 BIRC5 MUC1 TP53
13 gastric cancer, somatic 31.5 BIRC5 CDH1 CDKN2A CTNNB1 EGFR ERBB2
14 prostate cancer 31.3 AKT1 BIRC5 CDH1 CTNNB1 EGFR ERBB2
15 gastrointestinal stromal tumor 31.3 AKT1 CDKN2A EGFR TP53
16 choriocarcinoma 31.2 CDKN2A MUC1 SMAD4 TP53
17 atrophic gastritis 31.1 BRAF CDKN2A PTGS2 TP53
18 fibroma 30.8 BRAF KRAS MUC1
19 villous adenoma 30.7 AKT1 CDH1 CDKN2A CTNNB1 EGFR PTGS2
20 peritoneal mesothelioma 30.7 BRAF CDH1 CTNNB1 KRAS TP53
21 lung cancer 30.7 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
22 myxedema 30.6 CDKN2A EGFR TP53
23 olfactory neuroblastoma 30.4 EGFR KRAS TP53
24 esophagus squamous cell carcinoma 30.4 CDKN2A PTGS2 TP53
25 apocrine adenoma 30.3 BRAF CDKN2A EPCAM KRAS TP53
26 malignant struma ovarii 30.2 CTNNB1 PTGS2 TP53
27 colorectal cancer 30.0 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
28 mantle cell lymphoma 30.0 CDKN2A EGFR KDR TP53
29 nasopharyngeal carcinoma 29.9 CDKN2A EGFR TP53
30 hepatocellular carcinoma 29.5 AKT1 BIRC5 CDH1 CDKN2A CTNNB1 EPCAM
31 gallbladder cancer 29.4 AKT1 CDH1 CDKN2A CTNNB1 EGFR EPCAM
32 hypohidrosis 29.3 BRAF KRAS RB1 TP53
33 adrenal cortical carcinoma 27.7 AKT1 BIRC5 CDH1 CDKN2A CTNNB1 EGFR
34 sertoli-leydig cell tumor 26.9 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
35 appendix adenocarcinoma 12.1
36 clear cell adenocarcinoma 12.1
37 papillary adenocarcinoma 12.1
38 pancreas adenocarcinoma 12.1
39 pancreatic ductal adenocarcinoma 12.0
40 mucinous adenocarcinoma 12.0
41 small intestinal adenocarcinoma 12.0
42 aggressive digital papillary adenocarcinoma 11.9
43 scirrhous adenocarcinoma 11.9
44 bronchiolo-alveolar adenocarcinoma 11.9
45 tubular adenocarcinoma 11.9
46 signet ring cell adenocarcinoma 11.9
47 hepatoid adenocarcinoma 11.9
48 polymorphous low-grade adenocarcinoma 11.9
49 papillary serous adenocarcinoma 11.9
50 barrett esophagus/esophageal adenocarcinoma 11.9

Graphical network of the top 20 diseases related to Adenocarcinoma:



Diseases related to Adenocarcinoma

Symptoms & Phenotypes for Adenocarcinoma

GenomeRNAi Phenotypes related to Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 11.08 KRAS BRAF EGFR MUC1
2 Decreased viability GR00106-A-0 11.08 KRAS
3 Decreased viability GR00107-A-1 11.08 TGFBR2
4 Decreased viability GR00221-A-1 11.08 KRAS CDKN2A ROS1 TGFBR2 AKT1 CDH1
5 Decreased viability GR00221-A-2 11.08 KRAS KDR ROS1 AKT1 FGFR3
6 Decreased viability GR00221-A-3 11.08 KDR TGFBR2 AKT1 CDKN2A FGFR3 ERBB2
7 Decreased viability GR00221-A-4 11.08 TGFBR2 AKT1 CDKN2A EGFR BRAF KDR
8 Decreased viability GR00301-A 11.08 KRAS CDH1 BRAF ERBB4
9 Decreased viability GR00342-S-1 11.08 ROS1 ERBB4
10 Decreased viability GR00381-A-1 11.08 KRAS BRAF
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-10 10.43 FGFR3
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.43 TGFBR2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.43 TGFBR2
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.43 ERBB2
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.43 KDR TGFBR2
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.43 TGFBR2
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-20 10.43 TGFBR2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.43 AKT1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 10.43 TGFBR2
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.43 KDR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 10.43 FGFR3
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.43 AKT1 ERBB2 FGFR3 KDR TGFBR2
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.43 TGFBR2
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.43 TGFBR2
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.43 ERBB2
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 10.43 KDR
27 Decreased cell migration GR00055-A-1 10.11 AKT1 BRAF CTNNB1 EGFR ERBB4 FGFR3
28 Decreased viability in esophageal squamous lineage GR00235-A 10.06 BRAF CDH1 CDKN2A CTNNB1 ERBB2 FGFR3
29 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.98 CTNNB1 EGFR EPCAM ERBB2 ERBB4 FGFR3
30 Increased cell death HMECs cells GR00103-A-0 9.73 CTNNB1 EGFR ERBB4 TGFBR2 TP53 BIRC5
31 Increased cell migration GR00055-A-3 9.63 BRAF CTNNB1 EGFR ERBB4 KDR KRAS
32 Increased cell viability after pRB stimulation GR00230-A-1 9.35 AKT1 EGFR ERBB2 ERBB4 TGFBR2
33 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 BRAF KDR ROS1 SMAD4 TGFBR2

MGI Mouse Phenotypes related to Adenocarcinoma:

44 (show all 28)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.6 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
2 cardiovascular system MP:0005385 10.53 PTGS2 RB1 SMAD4 TGFBR2 TP53 AKT1
3 embryo MP:0005380 10.53 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
4 behavior/neurological MP:0005386 10.51 BRAF CDKN2A CTNNB1 EPCAM ERBB2 ERBB4
5 endocrine/exocrine gland MP:0005379 10.5 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
6 homeostasis/metabolism MP:0005376 10.5 EGFR EPCAM ERBB2 FGFR3 KDR KRAS
7 growth/size/body region MP:0005378 10.49 AKT1 BRAF CDH1 CDKN2A CTNNB1 EGFR
8 immune system MP:0005387 10.49 FGFR3 KDR KRAS PTGS2 RB1 SMAD4
9 hematopoietic system MP:0005397 10.48 FGFR3 KDR KRAS PTGS2 RB1 SMAD4
10 digestive/alimentary MP:0005381 10.46 BRAF CDH1 CDKN2A CTNNB1 EGFR EPCAM
11 mortality/aging MP:0010768 10.46 AKT1 BIRC5 BRAF CDH1 CDKN2A CTNNB1
12 integument MP:0010771 10.42 AKT1 BRAF RB1 SMAD4 TP53 CDH1
13 craniofacial MP:0005382 10.36 BRAF CTNNB1 EGFR ERBB2 ERBB4 FGFR3
14 nervous system MP:0003631 10.36 EPCAM ERBB2 ERBB4 FGFR3 KDR KRAS
15 muscle MP:0005369 10.34 AKT1 BRAF CDKN2A CTNNB1 EGFR ERBB2
16 neoplasm MP:0002006 10.32 PTGS2 RB1 SMAD4 TGFBR2 TP53 AKT1
17 normal MP:0002873 10.31 CTNNB1 EGFR AKT1 BIRC5 BRAF CDH1
18 liver/biliary system MP:0005370 10.3 AKT1 BRAF CDKN2A CTNNB1 EGFR KDR
19 no phenotypic analysis MP:0003012 10.21 CDH1 CDKN2A CTNNB1 EGFR EPCAM FGFR3
20 adipose tissue MP:0005375 10.18 BRAF EGFR PTGS2 RB1 TGFBR2 TP53
21 limbs/digits/tail MP:0005371 10.14 CTNNB1 EGFR ERBB2 FGFR3 KRAS RB1
22 hearing/vestibular/ear MP:0005377 10.13 BRAF CTNNB1 EGFR FGFR3 KRAS RB1
23 reproductive system MP:0005389 10.13 SMAD4 TP53 AKT1 BRAF CDH1 CDKN2A
24 respiratory system MP:0005388 10 TGFBR2 TP53 AKT1 BRAF CDKN2A CTNNB1
25 renal/urinary system MP:0005367 9.97 BRAF CTNNB1 EGFR FGFR3 KRAS PTGS2
26 pigmentation MP:0001186 9.91 EGFR KRAS RB1 TP53 BRAF CDKN2A
27 skeleton MP:0005390 9.8 CDKN2A CTNNB1 EGFR ERBB2 FGFR3 KDR
28 vision/eye MP:0005391 9.36 BRAF CDKN2A CTNNB1 EGFR FGFR3 KDR

Drugs & Therapeutics for Adenocarcinoma

FDA approved drugs:

(show all 11)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abraxane 17 46 PACLITAXEL Celgene October 2012
2
Cervarix 17 46 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
3
Cyramza 17 46 RAMUCIRUMAB Eli Lilly April 2014
4
Eloxatin 17 46 OXALIPLATIN Sanofi-aventis August 2002
5
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
6
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
7
Gilotrif 17 46 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
8
Herceptin 17 46 TRASTUZUMAB Genentech October 1998
9
Iressa 17 46 GEFITINIB AstraZeneca May 2003
10
Sutent 17 46 SUNITINIB MALATE Pfizer May 2011/ January 2006
11
Taxotere 17 46 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1045)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
2
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
3
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95058-81-4 60750
4
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
5
Clarithromycin Approved Phase 4 81103-11-9 84029
6
Metronidazole Approved Phase 4,Phase 2,Phase 1 443-48-1 4173
7
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
8
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
9
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 61825-94-3 5310940 9887054 43805 6857599
10
Propranolol Approved, Investigational Phase 4,Phase 2 525-66-6 4946
11
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 142217-69-4 153941
12
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
13
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
14
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
15
Ethiodized oil Approved Phase 4,Phase 2,Phase 3,Phase 1 8008-53-5
16
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 284461-73-0 216239 406563
17
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
18
Telbivudine Approved, Investigational Phase 4,Phase 1 3424-98-4 159269
19
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 198153-51-4 5360545
20
Ribavirin Approved Phase 4,Phase 3,Phase 2 36791-04-5 37542
21
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
22
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
23
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
24
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
25
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
26
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
27
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
29
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
30
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
31
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
32
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
33
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
34
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 2 142340-99-6 60871
35
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-43-4 5816
36 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
38
Nicotine Approved Phase 4,Phase 3 54-11-5 942 89594
39
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
40
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
41
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68538-85-2
42
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
43
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1 128794-94-5 5281078
44
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1 24280-93-1 446541
45
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
46
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83150-76-9 383414 6400441
47
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
48
Zinc Approved Phase 4,Phase 2,Phase 1 7440-66-6 32051 23994
49
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
50
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903

Interventional clinical trials:

(show top 50) (show all 6960)

id Name Status NCT ID Phase Drugs
1 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
2 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
3 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
4 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
5 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
6 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
7 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent Unknown status NCT00746538 Phase 4
8 Preoperative Biliary Drainage for Resectable Hilar Cholangiocarcinoma Unknown status NCT00797121 Phase 4
9 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
10 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
11 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
12 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
13 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
14 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
15 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
16 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
17 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
18 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
19 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
20 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
21 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
22 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
23 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
24 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
25 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
26 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
27 Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma Unknown status NCT00294177 Phase 4
28 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
29 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
30 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
31 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
32 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
33 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
34 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
35 A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma Completed NCT00097578 Phase 4
36 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
37 Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion Completed NCT01451034 Phase 4
38 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
39 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
40 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
41 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
42 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4 rabeprazole;placebo
43 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4 intrarectal lidocaine gel anesthesia;periprostatic nerve blockade
44 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
45 Prospective Randomized Study of SILS Versus CLS for Rectal Cancer Completed NCT01579721 Phase 4
46 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
47 Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET Completed NCT00904410 Phase 4
48 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
49 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
50 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma Completed NCT00721175 Phase 4

Search NIH Clinical Center for Adenocarcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: adenocarcinoma

Genetic Tests for Adenocarcinoma

Genetic tests related to Adenocarcinoma:

id Genetic test Affiliating Genes
1 Adenocarcinoma 29

Anatomical Context for Adenocarcinoma

MalaCards organs/tissues related to Adenocarcinoma:

39
Lung, Prostate, Liver, Kidney, Colon, Breast, Pancreas

Publications for Adenocarcinoma

Articles related to Adenocarcinoma:

(show top 50) (show all 14924)
id Title Authors Year
1
Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma. ( 28952227 )
2017
2
Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. ( 28533893 )
2017
3
Nonspecific granulomatous prostatitis in association with eosinophilic epithelial metaplasia and prostatic adenocarcinoma. ( 28937384 )
2017
4
Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma. ( 28558381 )
2017
5
HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma. ( 28588175 )
2017
6
DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. ( 27959420 )
2017
7
Long-term Trends in Primary Sites of Gastric Adenocarcinoma in Japan and the United States. ( 28819392 )
2017
8
Dyskeratosis congenita, bone marrow failure, and gastric adenocarcinoma: an insight into telomere biology. ( 28699608 )
2017
9
Selective cytotoxicity of vanadium complexes on human pancreatic ductal adenocarcinoma cell line by inducing necroptosis, apoptosis and mitotic catastrophe process. ( 28947974 )
2017
10
Cytological features of adenocarcinoma admixed with small cell neuroendocrine carcinoma of the uterine cervix. ( 28603541 )
2017
11
Invasive mucinous adenocarcinoma with lepidic-predominant pattern coexisted with tuberculosis: a case report. ( 28687977 )
2017
12
Adenocarcinoma of the Lung Acquiring Resistance to Afatinib by Transformation to Small Cell Carcinoma: A Case Report. ( 28878647 )
2017
13
Adenocarcinoma of Lung Presenting as Lambert-Eaton Myasthenic Syndrome. ( 28785598 )
2017
14
6-shogaol induces autophagic cell death then triggered apoptosis in colorectal adenocarcinoma HT-29 cells. ( 28641163 )
2017
15
Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. ( 28389666 )
2017
16
Presentation of mucinous adenocarcinoma of renal pelvis masquerading as gross hydronephrosis: A histopathological surprise. ( 28702413 )
2017
17
Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells. ( 28270066 )
2017
18
Prognostic significance of autophagy-related proteins expression in resected human gastric adenocarcinoma. ( 28224423 )
2017
19
Incidental Prostate Adenocarcinoma in Cystoprostatectomy Specimens: Partial Versus Complete Prostate Sampling. ( 28381150 )
2017
20
Ichthyosis Uteri Associated with Endometrial Adenocarcinoma: A Case Report. ( 28764184 )
2017
21
Giant mucinous adenocarcinoma of the appendix: a case report. ( 28756772 )
2017
22
Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. ( 28785956 )
2017
23
Implications of inflammation and remodeling of the enteric glial cells in colorectal adenocarcinoma. ( 28730232 )
2017
24
Novel perspective to evaluate the safety of segmentectomy: clinical significance of lobar and segmental lymph node metastasis in cT1N0M0 lung adenocarcinoma. ( 28950357 )
2017
25
Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome. ( 28501935 )
2017
26
Size of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria. ( 27744658 )
2017
27
Serum carcinoembryonic antigen specifically increases among various serum markers of adenocarcinoma in hypohidrosis or conditions related to hypohidrosis. ( 28295553 )
2017
28
Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma. ( 28912447 )
2017
29
Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation. ( 28345454 )
2017
30
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial. ( 28772306 )
2017
31
P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy. ( 28059963 )
2017
32
Late recurrence of colorectal adenocarcinoma as a renal tumour by direct spread via the ureter. ( 28588649 )
2017
33
Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach. ( 28377935 )
2017
34
A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. ( 28913565 )
2017
35
MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-I_B Pathway In Vitro. ( 28194669 )
2017
36
Metastatic cervical adenocarcinoma to the orbital subperiosteal space. ( 28457305 )
2017
37
Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients. ( 28056913 )
2017
38
Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. ( 28279716 )
2017
39
Iodine Concentration in Spectral CT: Assessment of Prognostic Determinants in Patients With Gastric Adenocarcinoma. ( 28871809 )
2017
40
Current Strategies for Detection and Treatment of Recurrence of Pancreatic Ductal Adenocarcinoma After Resection: A Nationwide Survey. ( 28902799 )
2017
41
Cystic splenomegaly: ectopic adenocarcinoma of unknown primary. ( 28663224 )
2017
42
MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. ( 28836853 )
2017
43
The Prostate in Female? Clear Cell Adenocarcinoma in a Female Urethral Diverticulum. ( 27789300 )
2017
44
Salvia fruticosa Modulates mRNA Expressions and Activity Levels of Xenobiotic Metabolizing CYP1A2, CYP2E1, NQO1, GPx, and GST Enzymes in Human Colorectal Adenocarcinoma HT-29 Cells. ( 28718679 )
2017
45
Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma. ( 28115165 )
2017
46
Image Diagnosis: A Gastric Signet-Ring Adenocarcinoma of Type Linitis Plastica Mimicking Splenomegaly in a Patient with Chronic Lymphocytic Leukemia. ( 28609263 )
2017
47
Adipose Triglyceride Lipase (ATGL) Expression Is Associated with Adiposity and Tumor Stromal Proliferation in Patients with Pancreatic Ductal Adenocarcinoma. ( 28179319 )
2017
48
Racial Disparities in Clinical Presentation and Survival Times Among Young-Onset Colorectal Adenocarcinoma. ( 28631085 )
2017
49
miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma. ( 28012229 )
2017
50
Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma. ( 28604449 )
2017